Omicron News and Research

RSS

The 2022 U.S. RSV surge consisted of a variety of pre-existing viruses

In a recent study posted to the medRxiv* preprint server, researchers investigated whether the upsurge in respiratory syncytial virus (RSV) infections during the autumn season of 2022 occurred due to the emergence of a novel, highly transmissible RSV strain or whether multiple pre-existing RSV strains were responsible for the increase in RSV case counts during the period.

12 Jan 2023

COVID-19 booster doses could significantly reduce the incidence of SARS-CoV-2 infection among young adults

A recent study published in the journal PLOS Medicine examined the effectiveness of booster doses of coronavirus disease 2019 (COVID-19) vaccines in protecting vaccinated young adults against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections during the dominant period of the Omicron BA.1 variant.

12 Jan 2023

New research identifies natural compounds with pan-SARS-CoV-2 inhibitory activity

Scientists have recently conducted a cell-based high-content screening of over 300 natural compounds and identified three compounds with potent antiviral activities against SARS-CoV-2 and its variants.

12 Jan 2023

The impact of prior SARS-CoV-2 infection and vaccination on Omicron infection

researchers explored the effects of prior SARS-CoV-2 infection and vaccination on SARS-CoV-2 Omicron infection.

12 Jan 2023

Study shows booster vaccinations against SARS-CoV-2 effective but protection wanes rapidly

A recent study posted to medRxiv* assessed the effectiveness of primary and booster vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the Netherlands.

11 Jan 2023

Bivalent boosters tested against all SARS-CoV-2 Omicron lineages

In a recent study posted to the bioRxiv* preprint server, researchers in the United States assessed the impact of the bivalent messenger ribonucleic acid (mRNA) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine on the antibody-mediated neutralization of the SARS-CoV-2 Omicron lineages.

11 Jan 2023

COVID-19 outcomes in Rituximab treated patients

A new report throws light on SARS-CoV-2 breakthrough infections in patients with certain joint diseases or musculoskeletal conditions who are on rituximab and compares the severity of COVID-19 outcomes in these patients whilst identifying potential risk factors for severe outcomes.

11 Jan 2023

2022: a year in MIS-C research

In a recent review published in Nature Reviews Rheumatology, researchers reviewed existing data on the multisystem inflammatory syndrome in children (or MIS-C).

11 Jan 2023

Real-world effectiveness of the bivalent vaccine for preventing COVID-19 hospitalizations in non-hospitalized subjects

Researchers investigated the efficacy of a booster dose of the bivalent mRNA COVID-19 vaccine in preventing severe outcomes during SARS-CoV-2 infections.

11 Jan 2023

Spike protein mutations in Omicron subvariants increase their susceptibility to reductive cleavage of disulfide bonds

Researchers discovered that the spike protein of SARS-CoV-2 is susceptible to cleavage at the disulfide bonds, and the vulnerability to reductive cleavage varies across variants, with the Omicron variant family being highly susceptible to reduction.

10 Jan 2023

Study explores incidence, severity, and long COVID associations of SARS-CoV-2 reinfections

Researchers used electronic health records to characterize the incidence, biomarkers, attributes, and severity of SARS-CoV-2 reinfections and evaluated the association between reinfections and long coronavirus disease (COVID).

10 Jan 2023

Profound immune escape by SARS-CoV-2 XBB.1 even after 4 vaccine doses

In a recent correspondence published in The Lancet Infectious Diseases journal, researchers in Germany assessed the neutralization sensitivity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) XBB.1 lineage.

9 Jan 2023

Compounds derived from B.C. sea sponge can prevent COVID-19 infection in human cells

UBC researchers have identified three compounds that prevent COVID-19 infection in human cells, derived from natural sources including a B.C. sea sponge.

9 Jan 2023

Researchers study the spatial distribution of SARS-CoV-2 Omicron BA.1 variant in England

Researchers performed a genomic assessment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant’s BA.1 subvariant transmission in England.

9 Jan 2023

Incidence rates and characteristics associated with medically attended COVID-19 episodes among infants younger than 6 months

A recent study estimated the overall incidence rates of medically attended SARS-CoV-2 infection among infants.

9 Jan 2023

Study reveals poor immunity against SARS-CoV-2 BQ.1.1 and XBB mutants in Norway

Researchers conducted a seroprevalence study in the general population of Norway, evaluating immunity against multiple subvariants of SARS-CoV-2 Omicron, including XBB and BQ.1.1 mutants.

9 Jan 2023

Research suggests people on rheumatoid arthritis drugs show weaker response to SARS-CoV-2 vaccines

Researchers conducted a comparative study among a cohort of individuals on rheumatoid arthritis (RA) therapies vis-à-vis healthy controls to assess their responses to coronavirus disease 2019 (COVID-19) vaccines.

9 Jan 2023

Is universal coronavirus immunity possible?

In a recent study posted to the bioRxiv* preprint server, researchers at Columbia University characterized reciprocal and non-reciprocal T-cell responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Jan 2023

New research on nirmatrelvir resistance in SARS-CoV-2 using powerful replicon cell culture systems

In a recent study posted to the bioRxiv* preprint server, researchers at Emory University used severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Washington (WA.1) and Omicron (BA.1) strains to test for mutations that could result in resistance to the antiviral drug nirmatrelvir.

8 Jan 2023

COVID-19 vaccine potency and breadth improved by nanoparticle-conjugated adjuvants

In a recent study posted to bioRxiv*, researchers designed a nanoparticle (NP)-conjugated toll-like receptor 9 (TLR9) agonist to improve the adjuvanticity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines.

8 Jan 2023

Omicron News and Research

The 2022 U.S. RSV surge consisted of a variety of pre-existing viruses

COVID-19 booster doses could significantly reduce the incidence of SARS-CoV-2 infection among young adults

New research identifies natural compounds with pan-SARS-CoV-2 inhibitory activity

The impact of prior SARS-CoV-2 infection and vaccination on Omicron infection

Study shows booster vaccinations against SARS-CoV-2 effective but protection wanes rapidly

Bivalent boosters tested against all SARS-CoV-2 Omicron lineages

COVID-19 outcomes in Rituximab treated patients

2022: a year in MIS-C research

Real-world effectiveness of the bivalent vaccine for preventing COVID-19 hospitalizations in non-hospitalized subjects

Spike protein mutations in Omicron subvariants increase their susceptibility to reductive cleavage of disulfide bonds

Study explores incidence, severity, and long COVID associations of SARS-CoV-2 reinfections

Profound immune escape by SARS-CoV-2 XBB.1 even after 4 vaccine doses

Compounds derived from B.C. sea sponge can prevent COVID-19 infection in human cells

Researchers study the spatial distribution of SARS-CoV-2 Omicron BA.1 variant in England

Incidence rates and characteristics associated with medically attended COVID-19 episodes among infants younger than 6 months

Study reveals poor immunity against SARS-CoV-2 BQ.1.1 and XBB mutants in Norway

Research suggests people on rheumatoid arthritis drugs show weaker response to SARS-CoV-2 vaccines

Is universal coronavirus immunity possible?

New research on nirmatrelvir resistance in SARS-CoV-2 using powerful replicon cell culture systems

COVID-19 vaccine potency and breadth improved by nanoparticle-conjugated adjuvants

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News